BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 31576538)

  • 21. AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial-mesenchymal transition in triple-negative breast cancer.
    Qiao Y; Shiue CN; Zhu J; Zhuang T; Jonsson P; Wright AP; Zhao C; Dahlman-Wright K
    Oncotarget; 2015 Apr; 6(10):7804-14. PubMed ID: 25762639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
    Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
    Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer.
    Bansal N; Petrie K; Christova R; Chung CY; Leibovitch BA; Howell L; Gil V; Sbirkov Y; Lee E; Wexler J; Ariztia EV; Sharma R; Zhu J; Bernstein E; Zhou MM; Zelent A; Farias E; Waxman S
    Oncotarget; 2015 Oct; 6(33):34087-105. PubMed ID: 26460951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
    Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
    Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
    Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
    Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
    Li K; Ying M; Feng D; Chen Y; Wang J; Wang Y
    Oncol Rep; 2016 Apr; 35(4):2405-12. PubMed ID: 26781859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
    Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
    J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
    Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
    Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pomegranate peel extract inhibits expression of β-catenin, epithelial mesenchymal transition, and metastasis in triple negative breast cancer cells.
    Bagheri M; Fazli M; Saeednia S; Kor A; Ahmadiankia N
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(7):86-91. PubMed ID: 29974851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.
    Luo CW; Wu CC; Chang SJ; Chang TM; Chen TY; Chai CY; Chang CL; Hou MF; Pan MR
    Exp Cell Res; 2018 Feb; 363(1):65-72. PubMed ID: 29305962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
    Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
    Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
    Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
    Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
    Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
    Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
    Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
    Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
    Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
    Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer.
    Dai M; Zhang C; Ali A; Hong X; Tian J; Lo C; Fils-Aimé N; Burgos SA; Ali S; Lebrun JJ
    Sci Rep; 2016 Oct; 6():35383. PubMed ID: 27759034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
    Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer.
    Srinivasan A; Thangavel C; Liu Y; Shoyele S; Den RB; Selvakumar P; Lakshmikuttyamma A
    Mol Carcinog; 2016 May; 55(5):743-56. PubMed ID: 25968914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.